It's common for clinical-stage biotech companies to post net losses, but the market wasn't forgiving of this one's latest.

Guidance remains unchanged, with management projecting "over $100 million in partnership inflows by the end of 2026" and targeting a cash burn below $390 million in 2026. The company anticipates a ...

A team dedicated to controlling populations of invasive Burmese pythons in South Florida has deployed another unique method ...

B stacks up against GPT-4o in practical tests. From coding to logic and creativity, here’s the side-by-side you’ve been ...